Expanded access to divarasib for advanced lung cancer with KRAS G12C mutation
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This program provides access to an investigational drug called divarasib for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It is for those whose cancer has grown after prior treatments, and it aims to see if the drug can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lung cancer must be advanced or spread and can't be removed with surgery or cured with radiation and chemotherapy together.
- Your cancer must have gotten worse after at least one prior treatment, but you must have had no more than three treatments for advanced disease.
- A test showing your cancer has the KRAS G12C mutation is required.
- You must be able to swallow whole tablets without chewing or crushing them.
- You must be generally well enough to be up and about (able to care for yourself, though not necessarily perform normal activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies divarasib to see if it is safe and can shrink or control advanced lung cancer. Participants must have a KRAS G12C mutation and have not had prior treatment for their advanced disease.
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
This study tests whether a drug called divarasib can help prevent lung cancer from coming back after surgery and initial treatment. You would only qualify if your cancer has a specific genetic mutation (KRAS G12C) and you've already had surgery and chemotherapy with immunotherapy.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This Phase 2 trial studies sotorasib, a targeted medicine, in people with non-small cell lung cancer (NSCLC) that has a specific KRAS mutation called G12C. You may be eligible if your cancer has spread or can’t be removed by surgery and has grown again after at least one previous treatment.
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.